Abstract
Allergic rhinitis (AR) is a common disease affecting young and otherwise healthy adults. In Mexico, the frequency of nasal symptoms like rhinorrhea, nasal congestion and itching is around 35% in AR patients. Ciclesonide (CIC) is a hypotonic intranasal corticosteroid with potent glucocorticoid-like anti-inflammatory activity, indicated for AR. Intranasal CIC is locally hydrolyzed by esterases to desisobutyryl-ciclesonide, the active metabolite with ∼120-fold greater affinity for glucocorticoid receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
